Non-MALT marginal zone lymphomas.
Thieblemont
C
C
Service d'hémato-oncologie, Hôpital Saint-Louis, Paris, France.
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007558:Italy / Q000453:epidemiology; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D008198:Lymph Nodes / Q000473:pathology; D008218:Lymphocytosis; D016393:Lymphoma, B-Cell / Q000473:pathology*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013156:Splenectomy; D013160:Splenic Neoplasms / Q000473:pathology / Q000601:surgery; D016019:Survival Analysis; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000032:analysis
D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001613:beta 2-Microglobulin; D004317:Doxorubicin; D007770:L-Lactate Dehydrogenase; D014740:Vidarabine; C024352:fludarabine